Last reviewed 2026-04-23 · How we verify

Glucocorticoids [Reduced Dose]

University of Pennsylvania · Phase 3 active Small molecule

Glucocorticoids [Reduced Dose] is a Glucocorticoid Small molecule drug developed by University of Pennsylvania. It is currently in Phase 3 development for Inflammatory and autoimmune conditions (specific indication under investigation in phase 3 trial).

Reduced-dose glucocorticoids suppress immune and inflammatory responses by binding to glucocorticoid receptors and modulating gene expression.

Reduced-dose glucocorticoids suppress immune and inflammatory responses by binding to glucocorticoid receptors and modulating gene expression. Used for Inflammatory and autoimmune conditions (specific indication under investigation in phase 3 trial).

Likelihood of approval

59.3% vs 58.3% industry baseline

If approved by FDA: likely 2028–2030

Steps remaining: NDA/BLA submission

Confidence: High

Why this estimate

Baseline phase 3 → approval rate +58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Immunology slight uplift +1.0pp
Mature endpoint landscape (ACR, DAS28, PASI) makes immunology approvals slightly more predictable.

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2028–2030	—
EMA	EU	2029–2031	+0.7 yr
MHRA	GB	2029–2031	+0.7 yr
Health Canada	CA	2029–2032	+0.9 yr
TGA	AU	2029–2032	+1.2 yr
PMDA	JP	2029–2032	+1.5 yr
NMPA	CN	2030–2033	+2.3 yr
MFDS	KR	2029–2032	+1.4 yr
CDSCO	IN	2029–2033	+1.8 yr
ANVISA	BR	2030–2033	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	Glucocorticoids [Reduced Dose]
Sponsor	University of Pennsylvania
Drug class	Glucocorticoid
Target	Glucocorticoid receptor (GR)
Modality	Small molecule
Therapeutic area	Immunology
Phase	Phase 3

Mechanism of action

Glucocorticoids are corticosteroids that work by entering cells and binding to intracellular glucocorticoid receptors, which then translocate to the nucleus and regulate transcription of anti-inflammatory and immunosuppressive genes. The reduced-dose formulation aims to maintain therapeutic efficacy while minimizing systemic adverse effects associated with standard glucocorticoid dosing. This approach is being investigated to improve the risk-benefit profile in chronic inflammatory and autoimmune conditions.

Approved indications

Inflammatory and autoimmune conditions (specific indication under investigation in phase 3 trial)

Common side effects

Hyperglycemia
Hypertension
Osteoporosis
Immunosuppression/increased infection risk
Adrenal suppression
Mood changes

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Glucocorticoids [Reduced Dose] CI brief — competitive landscape report
Glucocorticoids [Reduced Dose] updates RSS · CI watch RSS
University of Pennsylvania portfolio CI

Frequently asked questions about Glucocorticoids [Reduced Dose]

What is Glucocorticoids [Reduced Dose]?

Glucocorticoids [Reduced Dose] is a Glucocorticoid drug developed by University of Pennsylvania, indicated for Inflammatory and autoimmune conditions (specific indication under investigation in phase 3 trial).

How does Glucocorticoids [Reduced Dose] work?

Reduced-dose glucocorticoids suppress immune and inflammatory responses by binding to glucocorticoid receptors and modulating gene expression.

What is Glucocorticoids [Reduced Dose] used for?

Glucocorticoids [Reduced Dose] is indicated for Inflammatory and autoimmune conditions (specific indication under investigation in phase 3 trial).

Who makes Glucocorticoids [Reduced Dose]?

Glucocorticoids [Reduced Dose] is developed by University of Pennsylvania (see full University of Pennsylvania pipeline at /company/university-of-pennsylvania).

What drug class is Glucocorticoids [Reduced Dose] in?

Glucocorticoids [Reduced Dose] belongs to the Glucocorticoid class. See all Glucocorticoid drugs at /class/glucocorticoid.

What development phase is Glucocorticoids [Reduced Dose] in?

Glucocorticoids [Reduced Dose] is in Phase 3.

What are the side effects of Glucocorticoids [Reduced Dose]?

Common side effects of Glucocorticoids [Reduced Dose] include Hyperglycemia, Hypertension, Osteoporosis, Immunosuppression/increased infection risk, Adrenal suppression, Mood changes.

What does Glucocorticoids [Reduced Dose] target?

Glucocorticoids [Reduced Dose] targets Glucocorticoid receptor (GR) and is a Glucocorticoid.

Drug class: All Glucocorticoid drugs
Target: All drugs targeting Glucocorticoid receptor (GR)
Manufacturer: University of Pennsylvania — full pipeline
Therapeutic area: All drugs in Immunology
Indication: Drugs for Inflammatory and autoimmune conditions (specific indication under investigation in phase 3 trial)

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing